Moleculin Participates in Virtual Investor "What this Means" Segment
Moleculin Biotech, Inc. (Nasdaq: MBRX) has announced that CEO Walter Klemp participated in a Virtual Investor 'What this Means' segment. The segment focused on the company's Phase 2 clinical trial of WP1066, a STAT3 inhibitor, in combination with radiation therapy for the treatment of glioblastoma in adults. This investigator-initiated study (NU 21C06) is being conducted under Northwestern University's IND, which references Moleculin's FDA-cleared IND from April 2022.
The trial is funded by the National Institutes of Health (NIH) and BrainUp®, a non-profit organization dedicated to brain cancer awareness. Moleculin, a Phase 3 clinical-stage pharmaceutical company, is developing a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses. The Virtual Investor segment featuring Moleculin is now available for viewing online.
Moleculin Biotech, Inc. (Nasdaq: MBRX) ha annunciato che il CEO Walter Klemp ha partecipato a un segmento Virtual Investor chiamato 'What this Means'. Il segmento si è concentrato sul trial clinico di Fase 2 di WP1066, un inibitore di STAT3, in combinazione con la radioterapia per il trattamento del glioblastoma negli adulti. Questo studio avviato da un investigatore (NU 21C06) è condotto sotto l'IND della Northwestern University, che fa riferimento all'IND approvato dalla FDA di Moleculin risalente ad aprile 2022.
Il trial è finanziato dai National Institutes of Health (NIH) e da BrainUp®, un'organizzazione no-profit dedicata alla sensibilizzazione sul cancro al cervello. Moleculin, un'azienda farmaceutica in fase clinica 3, sta sviluppando un ampio portafoglio di candidati terapeutici per il trattamento di tumori e virus difficili da trattare. Il segmento Virtual Investor con Moleculin è ora disponibile per la visione online.
Moleculin Biotech, Inc. (Nasdaq: MBRX) ha anunciado que el CEO Walter Klemp participó en un segmento Virtual Investor titulado 'What this Means'. El segmento se centró en el ensayo clínico de Fase 2 de WP1066, un inhibidor de STAT3, en combinación con terapia de radiación para el tratamiento del glioblastoma en adultos. Este estudio iniciado por investigadores (NU 21C06) se lleva a cabo bajo el IND de la Universidad Northwestern, que hace referencia al IND aprobado por la FDA de Moleculin desde abril de 2022.
El ensayo está financiado por los National Institutes of Health (NIH) y BrainUp®, una organización sin fines de lucro dedicada a la concientización sobre el cáncer cerebral. Moleculin, una compañía farmacéutica en fase clínica 3, está desarrollando un amplio portafolio de candidatos a fármacos dirigidos a tumores y virus difíciles de tratar. El segmento de Virtual Investor que presenta a Moleculin ya está disponible para ver en línea.
Moleculin Biotech, Inc. (Nasdaq: MBRX)는 CEO Walter Klemp가 'What this Means'라는 제목의 가상 투자자 세션에 참여했다고 발표했습니다. 이 세션은 성인 교모세포종 치료를 위한 방사선 요법과 병용된 STAT3 억제제인 WP1066의 2상 임상 시험에 초점을 맞추었습니다. 이 연구(NU 21C06)는 Northwestern University의 IND 하에 진행되며, Moleculin의 2022년 4월 FDA 승인 IND를 참조합니다.
이 임상 시험은 국립 보건원(NIH)와 뇌암 인식에 헌신하는 비영리 단체 BrainUp®의 재정 지원을 받고 있습니다. Moleculin은 난치성 종양과 바이러스를 겨냥한 광범위한 약물 후보군을 개발 중인 임상 3상 제약 회사입니다. Moleculin이 포함된 가상 투자자 세션은 이제 온라인에서 시청 가능합니다.
Moleculin Biotech, Inc. (Nasdaq: MBRX) a annoncé que le PDG Walter Klemp a participé à un segment d'investisseur virtuel intitulé 'What this Means'. Le segment était axé sur l'essai clinique de Phase 2 de WP1066, un inhibiteur de STAT3, en combinaison avec la radiothérapie pour le traitement du glioblastome chez les adultes. Cette étude initiée par des chercheurs (NU 21C06) est menée sous l'IND de l'Université Northwestern, qui fait référence à l'IND approuvé par la FDA de Moleculin datant d'avril 2022.
L'essai est financé par les National Institutes of Health (NIH) et BrainUp®, une organisation à but non lucratif dédiée à la sensibilisation au cancer du cerveau. Moleculin, une entreprise pharmaceutique en phase clinique 3, développe un large portefeuille de candidats médicaments ciblant des tumeurs et des virus difficiles à traiter. Le segment d'investisseur virtuel mettant en vedette Moleculin est maintenant disponible pour visionnage en ligne.
Moleculin Biotech, Inc. (Nasdaq: MBRX) hat bekannt gegeben, dass CEO Walter Klemp an einem virtuellen Investorensegment mit dem Titel 'What this Means' teilgenommen hat. Das Segment konzentrierte sich auf die Phase-2-Studie von WP1066, einem STAT3-Inhibitor, in Kombination mit Strahlentherapie zur Behandlung von Glioblastomen bei Erwachsenen. Diese vom Forscher initiierte Studie (NU 21C06) wird unter IND der Northwestern University durchgeführt, die sich auf Moleculins von der FDA genehmigtes IND vom April 2022 bezieht.
Die Studie wird von den National Institutes of Health (NIH) und BrainUp®, einer gemeinnützigen Organisation, die sich der Bewusstseinsbildung über Gehirntumoren widmet, finanziert. Moleculin, ein Pharmaunternehmen in der klinischen Phase 3, entwickelt ein breites Portfolio von Arzneimittelkandidaten, die sich auf schwer behandelbare Tumoren und Viren konzentrieren. Das virtuelle Investorensegment mit Moleculin ist jetzt online verfügbar.
- Ongoing Phase 2 clinical trial for glioblastoma treatment
- Collaboration with Northwestern University for the study
- FDA clearance for the Investigational New Drug (IND) application
- Funding support from NIH and BrainUp® for the trial
- None.
Wally Klemp, CEO of Moleculin, discusses the Company's recent update on the Phase 2 clinical trial of STAT3 inhibitor in combination with radiation for the treatment of glioblastoma
Watch the "What This Means" video here
As part of the segment, Mr. Klemp highlighted the enrollment and treatment of patients in an investigator-initiated Phase 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with glioblastoma (NU 21C06). The study is being conducted under Northwestern University's Investigative New Drug application (IND) which cross references the Company's own IND, which received clearance from the
The Virtual Investor "What this Means" segment featuring Moleculin is now available here.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These forward-looking statements, include, but are not limited to, the ability for the study to fill the safety lead-in group of six subjects on a timely basis and whether the preclinical results will be demonstrated in the Phase 2 trial . These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-participates-in-virtual-investor-what-this-means-segment-302247934.html
SOURCE Moleculin Biotech, Inc.
FAQ
What is the focus of Moleculin's Phase 2 clinical trial for MBRX stock?
Who is funding the Phase 2 glioblastoma study for Moleculin (MBRX)?
When did Moleculin (MBRX) receive FDA clearance for their IND application?
What type of cancer is Moleculin (MBRX) targeting in their recent clinical trial?
